British girl has hearing restored as first patient on new gene therapy trial

Opal, 18 months old, was born completely deaf but can now hear almost as normal and could improve further

A British girl has had her hearing restored after becoming the first person in the world to take part in a groundbreaking new gene therapy trial.

Opal Sandy, aged 18 months, was born completely deaf due to the condition auditory neuropathy, which is caused by the disruption of nerve impulses travelling from the inner ear to the brain.

Hide Ad
Hide Ad

Now, thanks to a “one and done” gene therapy being trialled in the UK and worldwide, Opal’s hearing is almost normal – and could even improve further.

Opal Sandy, second left, who was born completely deaf because of a rare genetic condition, and can now hear unaided for the first time after receiving ground-breaking gene therapy at 11-months-old, pictured with her mother Jo, father James and sister Nora, at their home in Eynsham, Oxfordshire. Photo: Andrew Matthews/PA WireOpal Sandy, second left, who was born completely deaf because of a rare genetic condition, and can now hear unaided for the first time after receiving ground-breaking gene therapy at 11-months-old, pictured with her mother Jo, father James and sister Nora, at their home in Eynsham, Oxfordshire. Photo: Andrew Matthews/PA Wire
Opal Sandy, second left, who was born completely deaf because of a rare genetic condition, and can now hear unaided for the first time after receiving ground-breaking gene therapy at 11-months-old, pictured with her mother Jo, father James and sister Nora, at their home in Eynsham, Oxfordshire. Photo: Andrew Matthews/PA Wire

The little girl, from Oxfordshire, who has a genetic form of auditory neuropathy, was treated at Addenbrooke’s Hospital, which is part of Cambridge University Hospitals NHS Foundation Trust.

Professor Manohar Bance, an ear surgeon at the trust and chief investigator for the trial, said the results were “better than I hoped or expected” and may cure patients with this type of deafness.

He said: “We have results from (Opal) which are very spectacular – so close to normal hearing restoration. So we do hope it could be a potential cure.”

Auditory neuropathy can be caused by a fault in the OTOF gene, which is responsible for making a protein called otoferlin. This enables cells in the ear to communicate with the hearing nerve.

To overcome the fault, the “new era” gene therapy – from biotech firm Regeneron – delivers a working copy of the gene to the ear.

In Opal’s case, she received an infusion containing the working gene to her right ear during surgery last September.

Her parents Jo and James, both 33, noticed improvements to her hearing in four weeks when Opal turned her head to loud clapping.

Hide Ad
Hide Ad

“When she first turned, I couldn’t believe it,” Mrs Sandy said.

“I thought it was a fluke or like a change in light or something that had caught her eye, but I repeated it a few times.”

“I picked my phone up and texted James, and said ‘I think it’s working’. I was absolutely gobsmacked. I thought it was a fluke.”

But even more impressive results were on the horizon.

Some 24 weeks after surgery, in February this year, tests in Cambridge showed Opal could also hear soft sounds such as a whisper.

“The audiologist played back some of the sounds that she was responding to and they were ridiculously quiet sort of sounds that in the real world wouldn’t catch your attention during a conversation,” Mrs Sandy said.

“Certainly since February, we’ve noticed her sister (Nora) waking her up in the morning because she’s running around on the landing, or someone rings on the door so her nap’s cut short.

“She’s definitely responding more to sort of what we would call functional sounds rather than just sounds that we use to test her.

“We were told she had near normal hearing last time – I think they got responses at sort of 25 to 30 decibels.

Hide Ad
Hide Ad

“I think normal hearing is classed at 20 decibels, so she’s not far off. Before, she had no hearing whatsoever.”

Up to 18 youngsters from the UK, Spain and the US are being recruited to the trial and will be followed up for five years.

Comments

 0 comments

Want to join the conversation? Please or to comment on this article.